Literature DB >> 15054045

Positive and negative regulatory roles of the WW-like domain in TEL-PDGFbetaR transformation.

Jing Chen1, Ifor R Williams, Jeffery L Kutok, Nicole Duclos, Ema Anastasiadou, Shane C Masters, Haian Fu, D Gary Gilliland.   

Abstract

TEL-platelet-derived growth factor-beta receptor (TEL-PDGFbetaR) is expressed in chronic myelomonocytic leukemias associated with t(5;12)(q33;p13), and the fusion tyrosine kinase retains a conserved WW-like domain in the PDGFbetaR autoinhibitory juxtamembrane region. Here we report that mutation of the 2 conserved tryptophan residues of the WW-like domain has opposing effects on TELPDGFbetaR kinase activation. Alanine substitution of W593, essential for protein-protein interaction in the context of other WW domains, impaired TEL-PDGFbetaR-mediated transformation of hematopoietic cells due to inhibition of TEL-PDGFbetaR kinase activity. In contrast, alanine substitution of W566, essential for structural integrity of WW domain in other contexts, had no effect on TEL-PDGFbetaR activation and oncogenic activity. Surprisingly, however, the W566A mutation suppressed the W593A phenotype. Double mutant W566A/W593A was indistinguishable from the wild-type fusion protein with regard to kinase activity, ability to confer factor-independent growth to Ba/F3 cells, or ability to induce a myeloproliferative disease in mice. Additional mutational analysis identified other substitutions within the WW-like domain in addition to W566A that could also suppress the W593A phenotype, including mutations predicted to diminish the autoinhibitory function of the juxtamembrane region. Therefore, the WW-like domain in the context of TELPDGFbetaR may have both positive and negative regulatory roles in kinase activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15054045     DOI: 10.1182/blood-2004-01-0169

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.

Authors:  Jing Chen; Ifor R Williams; Benjamin H Lee; Nicole Duclos; Brian J P Huntly; Daniel J Donoghue; D Gary Gilliland
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

2.  Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.

Authors:  Philipp Erben; Darko Gosenca; Martin C Müller; Jelena Reinhard; Joannah Score; Francesco Del Valle; Christoph Walz; Jürgen Mix; Georgia Metzgeroth; Thomas Ernst; Claudia Haferlach; Nicholas C P Cross; Andreas Hochhaus; Andreas Reiter
Journal:  Haematologica       Date:  2010-01-27       Impact factor: 9.941

3.  The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.

Authors:  Elizabeth H Stover; Jing Chen; Benjamin H Lee; Jan Cools; Elizabeth McDowell; Jennifer Adelsperger; Dana Cullen; Allison Coburn; Sandra A Moore; Rachel Okabe; Doriano Fabbro; Paul W Manley; James D Griffin; D Gary Gilliland
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

4.  Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11).

Authors:  Guangying Sheng; Zhao Zeng; Jinlan Pan; Linbing Kou; Qinrong Wang; Hong Yao; Lijun Wen; Liang Ma; Depei Wu; Huiying Qiu; Suning Chen
Journal:  Mol Cytogenet       Date:  2017-02-27       Impact factor: 2.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.